Prevalence and distribution of harms
Harms were reported by 4% (n=138/3691) of those who responded to one or more harm question on the exit survey. Of those reporting harm, 9% (n=13/138) of participants reported >1 harm and 1% (n=2/138) >2 harms. Additionally, 0.7% (n=2/3061) reported a false positive elsewhere in the trial.Negative impacts to relationships from participating in SELPHI or using HIVST kits were reported by 1% (n=25/2675) in BT, nRT and RT combined, with no substantial differences by trial arm (Types of harm by trial arm*Data not collected for nBT.Qualitative study participant demographicsEthnicity not reported because of risk of deductive disclosure.Negative impacts on well-being were reported by 1% (n=37/2658) in BT, nRT and RT combined. Being pressured or persuaded to test when a participant did not want to was reported by 1% (n=54/3678). False positive test results were reported by 0.7% (n=34/4665) of participants overall, and similarly across trial arms. Two were reported during the trial, and a further 32 in end of study surveys. No participant reported multiple false positive results (